Pirkko Kellokumpu‐Lehtinen
- Oncology top 1%
- Molecular Biology top 10%
- Cancer Research top 2%
- Pulmonary and Respiratory Medicine top 2%
- Immunology top 5%
- Co-authors
- Ulla-Sisko LehtoPetri BonoVesa KatajaHeikki JoensuuL. J. PelliniemiMark J. SmythCarsten DenkertSibylle Loibl
- Topics
- Cancer Treatment and Pharmacology (24 papers)Breast Cancer Treatment Studies (14 papers)Prostate Cancer Treatment and Research (11 papers)
- Partner nations
- FinlandSwedenUnited States
In The Last Decade
Pirkko Kellokumpu‐Lehtinen
141 papers receiving 4.6k citations
Hit Papers
Peers
Comparison fields: 5 of 148
- Oncology 2.4k
- Molecular Biology 1.1k
- Cancer Research 995
- Pulmonary and Respiratory Medicine 993
- Immunology 617
Countries citing papers authored by Pirkko Kellokumpu‐Lehtinen
This map shows the geographic impact of Pirkko Kellokumpu‐Lehtinen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pirkko Kellokumpu‐Lehtinen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pirkko Kellokumpu‐Lehtinen more than expected).
Fields of papers citing papers by Pirkko Kellokumpu‐Lehtinen
This network shows the impact of papers produced by Pirkko Kellokumpu‐Lehtinen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pirkko Kellokumpu‐Lehtinen. The network helps show where Pirkko Kellokumpu‐Lehtinen may publish in the future.
Co-authorship network of co-authors of Pirkko Kellokumpu‐Lehtinen
This figure shows the co-authorship network connecting the top 25 collaborators of Pirkko Kellokumpu‐Lehtinen. A scholar is included among the top collaborators of Pirkko Kellokumpu‐Lehtinen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pirkko Kellokumpu‐Lehtinen. Pirkko Kellokumpu‐Lehtinen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 95 | |
| 3 | 9 | |
| 4 | 55 | |
| 5 | 34 | |
| 6 | No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer. | 2 |
| 7 | 20 | |
| 8 | Impact of radiotherapy and chemotherapy on biomarkers of oxidative DNA damage in lung cancer patients | 2 |
| 9 | 23 | |
| 10 | 27 | |
| 11 | 55 | |
| 12 | 7 | |
| 13 | 217 | |
| 14 | 3 | |
| 15 | 6 | |
| 16 | 43 | |
| 17 | 14 | |
| 18 | 3 | |
| 19 | 107 | |
| 20 | 20 |
About Pirkko Kellokumpu‐Lehtinen
Pirkko Kellokumpu‐Lehtinen is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 143 papers that have together received 4.7k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (24 papers), Breast Cancer Treatment Studies (14 papers) and Prostate Cancer Treatment and Research (11 papers). The work is most often cited by research in Oncology (2.4k citations), Cancer Research (995 citations) and Pulmonary and Respiratory Medicine (993 citations). Pirkko Kellokumpu‐Lehtinen has collaborated with scholars based in Finland, Sweden and United States. Frequent co-authors include Ulla-Sisko Lehto, Petri Bono, Vesa Kataja, Heikki Joensuu, L. J. Pelliniemi, Mark J. Smyth, Carsten Denkert, Sibylle Loibl, Martine Piccart and Christine Desmedt. Their work appears in journals such as The Lancet, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.